乌司他丁联合胸腺肽α1与急性呼吸窘迫综合征患者免疫调理作用的相关性分析

Analysis of Immunoregulation of Ustatime Companied by Thymosin in the Patients with Acute Respiratory Distress Syndrom

目的：探讨乌司他丁联合胸腺肽d1对急性呼吸窘迫综合征（ARDS）患者免疫调理作用的影响。方法：选择我科2009年6月～2012年6月收治的ARDS患者118例，随机分为实验组59例和对照组59例，两组患者均采用常规基础治疗（包括全胃肠外营养），实验组在此基础上给予乌司他丁联合胸腺肽n1免疫调理治疗，疗程为7d。采用酶联免疫吸附测定法检测血清TNF－α与IL－6水平及外周血淋巴细胞计数；采用流式细胞术检测外周血CD14’单核细胞人白细胞抗原DR（HLA－DR）表达率；统计患者ICU住院天数以及28d病死率。结果：治疗7d后，治疗组血清TNF－α与IL－6水平较对照组显著下降，淋巴细胞计数显著升高，差异均有统计学意义（P〈0．05，P〈0．01）；治疗7d后，治疗组CD14’单核细胞HLA－DR表达较对照组有明显上升（P〈0．05）；两组ICU住院时间比较，差异有统计学意义（P〈0．05）；28d病死率对照组为40％，治疗组为37．5％，两组病死率比较，差异无统计学意义（P〉0．05）。结论：乌司他丁联合胸腺肽α1免疫调理治疗能够一定程度改善ARDS患者的免疫机能，缩短住院时间，有利于ARDS患者的恢复，值得临床推广。

OBJECTIVE： To explore the effect of immunoregulation of Ustatine companied by thymosin in the patients with acute respiratory distress syndrom （ARDS）. METHODS： 118 patients with ARDS in our hospital from June in 2009 to June in 2012 were enrolled and divided into experimental group （n = 59 ） and control group （n = 59）. The both group all received the routine therepy. And experiment group accepted the treatment of Ustatine companied by thymosin at the same time lasting 7 days. The levels of TNF - α and IL- 6 were measured by enzyme linked immunosorbent assay （ELISA）. And the numbers of lymphocyte were calculated. The fatality rate was collected statistics. RESULTS ： After treatment the levels of TNF - α and IL - 6 in the treatment group increased clearly than those in the control group. There was statiscally differance （P 〈0. 05, P 〈0. 01 ）. The fatality rate was 40% in the con- trol group and 37.5% in the treatment group. There was no statiscally difference （P 〈 0. 05 ）. CONCLUSION： Ustatine companied by thymosin are effect in the patieats with ARDS.